Last reviewed · How we verify
A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults
The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults. The main question it aims to answer is: What is the difference in change in body weight and body mass index (BMI) from baseline at Day 84 between MB-1 and placebo? Participants will be provided MB-1 or placebo and be assessed for anthropometric measurements, blood pressure, heart rate, and asked to complete appetite and satiety questionnaires and undergo a DEXA scan.
Details
| Lead sponsor | Arrae |
|---|---|
| Phase | NA |
| Status | NOT_YET_RECRUITING |
| Enrolment | 100 |
| Start date | 2026-04 |
| Completion | 2026-07 |
Conditions
- Obese
- Overweight Adults
- Obese Adults
- Body Weight Control
- BMI
Interventions
- MB-1
- Placebo
Primary outcomes
- The difference in change in body weight and body mass index (BMI) between MB-1 and placebo — Day 0 to 84
The difference in change in body weight and body mass index (BMI) from baseline at Day 84 between MB-1 and placebo
Countries
Canada